Koyfin Home > Directory > Health Care > Amag Pharmaceuticals > EBITDA / Interest Expenses

Amag Pharmaceuticals EBITDA / Interest Expenses Chart (AMAG)

Amag Pharmaceuticals annual/quarterly EBITDA / Interest Expenses from 2014 to 2020. EBITDA / Interest is the interest coverage ratio and measures the ability of a company to service its debt.
  • Amag Pharmaceuticals EBITDA / Interest Expenses for the quarter ending June 06, 2020 was $-2m a -7.96% increase of 0m year over year
  • Amag Pharmaceuticals EBITDA / Interest Expenses for the last 12 months ending June 06, 2020 was $-3m a -43.49% increase of 1m year over year
  • Amag Pharmaceuticals Annual EBITDA / Interest Expenses for 2019 was $-4m a 144.26% decrease of -6m from 2018
  • Amag Pharmaceuticals Annual EBITDA / Interest Expenses for 2018 was $2m a -28.80% decrease of -1m from 2017
  • Amag Pharmaceuticals Annual EBITDA / Interest Expenses for 2017 was $2m a -27.97% decrease of -1m from 2016
Other Ratios Metrics:
  • Amag Pharmaceuticals Total Debt / Capital for the quarter ending September 09, 2018 was $27m a -79.63% decrease of -21m year over year
  • Amag Pharmaceuticals Other Liabilities for the quarter ending December 12, 2018 was $1m a -3,223.97% decrease of -46m year over year
  • Amag Pharmaceuticals Total Debt / Equity for the quarter ending September 09, 2018 was $37m a -153.66% decrease of -56m year over year
View Chart On Koyfin

Quarterly AMAG EBITDA / Interest Expenses Data

06/2020$-2m
03/2020$-2m
12/2019$-6m
09/2019$-2m
06/2019$-5m
03/2019$-5m
12/2018$-2m
09/2018$2m
06/2018$4m
03/2018$2m

Annual AMAG EBITDA / Interest Expenses Data

2019$-4m
2018$2m
2017$2m
2016$3m
2015$4m
2014$1m